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Abstract
Background
Bempedoic acid is a first-in-class lipid-lowering drug recommended by guidelines for the
treatment of hypercholesterolemia. Our objective was to estimate its average effect on
plasma lipids in humans and its safety profile.
Methods and findings
We carried out a systematic review and meta-analysis of phase II and III randomized con-
trolled trials on bempedoic acid (PROSPERO: CRD42019129687). PubMed (Medline), Sco-
pus, Google Scholar, and Web of Science databases were searched, with no language
restriction, from inception to 5 August 2019. We included 10 RCTs (n = 3,788) comprising
26 arms (active arm [n = 2,460]; control arm [n = 1,328]). Effect sizes for changes in lipids
and high-sensitivity C-reactive protein (hsCRP) serum concentration were expressed as
mean differences (MDs) and 95% confidence intervals (CIs). For safety analyses, odds
ratios (ORs) and 95% CIs were calculated using the Mantel–Haenszel method. Bempedoic
acid significantly reduced total cholesterol (MD −14.94%; 95% CI −17.31%, −12.57%; p <
0.001), non-high-density lipoprotein cholesterol (MD −18.17%; 95% CI −21.14%, −15.19%;
p < 0.001), low-density lipoprotein cholesterol (MD −22.94%; 95% CI −26.63%, −19.25%; p
< 0.001), low-density lipoprotein particle number (MD −20.67%; 95% CI −23.84%, −17.48%;
p < 0.001), apolipoprotein B (MD −15.18%; 95% CI −17.41%, −12.95%; p < 0.001), high-
density lipoprotein cholesterol (MD −5.83%; 95% CI −6.14%, −5.52%; p < 0.001), high-den-
sity lipoprotein particle number (MD −3.21%; 95% CI −6.40%, −0.02%; p = 0.049), and
hsCRP (MD −27.03%; 95% CI −31.42%, −22.64%; p < 0.001). Bempedoic acid did not
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significantly modify triglyceride level (MD −1.51%; 95% CI −3.75%, 0.74%; p = 0.189), very-
low-density lipoprotein particle number (MD 3.79%; 95% CI −9.81%, 17.39%; p = 0.585),
and apolipoprotein A-1 (MD −1.83%; 95% CI −5.23%, 1.56%; p = 0.290). Treatment with
bempedoic acid was positively associated with an increased risk of discontinuation of treat-
ment (OR 1.37; 95% CI 1.06, 1.76; p = 0.015), elevated serum uric acid (OR 3.55; 95% CI
1.03, 12.27; p = 0.045), elevated liver enzymes (OR 4.28; 95% CI 1.34, 13.71; p = 0.014),
and elevated creatine kinase (OR 3.79; 95% CI 1.06, 13.51; p = 0.04), though it was strongly
associated with a decreased risk of new onset or worsening diabetes (OR 0.59; 95% CI
0.39, 0.90; p = 0.01). The main limitation of this meta-analysis is related to the relatively
small number of individuals involved in the studies, which were often short or middle term in
length.
Conclusions
Our results show that bempedoic acid has favorable effects on lipid profile and hsCRP levels
and an acceptable safety profile. Further well-designed studies are needed to explore its
longer-term safety.
Author summary
Why was this study done?
• Lowering low-density lipoprotein cholesterol (LDL-C) is effective for reducing cardio-
vascular events over time.
• A number of phase II and phase III randomized controlled trials (RCTs) are already
available showing encouraging results of bempedoic acid treatment on LDL-C.
• We aimed to perform a systematic review and meta-analysis on the clinical evidence
available to date to better define the efficacy and tolerability profile of treatment with
bempedoic acid.
What did the researchers do and find?
• In this analysis of bempedoic acid that included 10 randomized clinical trials (n = 3,788
patients) comprising 26 arms (active arm [n = 2,460]; control arm [n = 1,328]), we con-
firmed that bempedoic acid significantly reduced total cholesterol (by 15%), non-high-
density lipoprotein cholesterol (by 18.2%), LDL-C (by 22.9%), low-density lipoprotein
particle number (by 20.7%), apolipoprotein B (by 15.2%), and high-sensitivity C-reac-
tive protein (hsCRP) (by 27%), while negatively affecting serum levels of high-density
lipoprotein cholesterol (−5.8%) and high-density lipoprotein particle number (−3.2%).
• Our results also confirmed that the therapy is overall safe and well tolerated, with no sig-
nificant increase of serious adverse effects.
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What do these findings mean?
• The current meta-analysis demonstrates the multiple positive effects of bempedoic acid
on lipid profile and hsCRP serum levels, as well as acceptable safety profile.
• This could be relevant in a setting where statin intolerance is very frequent and the
LDL-C target suggested by international guidelines for dyslipidemia management is
hard to achieve with standard therapies.
• An ongoing long-term cardiovascular outcomes trial will answer questions on the effect
of bempedoic acid on cardiovascular events and mortality as well as on the drug’s safety
issues.
Introduction
Cardiovascular diseases (CVDs) are still the leading cause of disability and death in developed
countries [1]. As reported by Mendelian randomization studies, a lifetime reduction of low-
density lipoprotein cholesterol (LDL-C) of 1 mmol/l might reduce the potential risk of athero-
sclerotic CVDs by over 50% [2]. Controlled clinical studies successfully showed a consistent
relationship between the reduction of LDL-C and cardiovascular (CV) risk decrease [3], such
that lipid-lowering therapy became a cornerstone in CV risk reduction.
Bempedoic acid (8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid; ETC-1002; Esper-
ion Therapeutics, Ann Arbor, MI) is a first-in-class small-molecule inhibitor of ATP citrate
lyase (ACLY), a key enzyme that supplies substrate for cholesterol and fatty acid synthesis [4].
ACLY is essential for growth and development, such that homozygous knockout (Acly−) in
mice is embryonic lethal, indicating non-redundancy during development [5]. By inhibiting
ACLY, bempedoic acid induces LDL receptor upregulation and stimulates the uptake of LDL
particles by the liver, which contributes to reduction of LDL-C concentration in the blood [6].
Bempedoic acid is administered orally once a day, is quickly absorbed in the small intestine,
and has a half-life ranging from 15 to 24 hours [7]. It is a prodrug that is activated by very-
long-chain acyl-CoA synthetase 1, an enzyme that is synthesized only in the liver [8]. Even
though bempedoic acid acts on the same pathway as statins (3-hydroxy-3-methylglutaryl coen-
zyme A reductase inhibitors), the lack of the activating enzyme in skeletal muscle may prevent
the muscular adverse effects associated with statins [8]. For this reason, bempedoic acid may
represent a novel treatment to reach LDL-C goals for statin-intolerant patients [9].
A number of phase II and phase III randomized controlled trials (RCTs) are already avail-
able, showing encouraging effects of bempedoic acid treatment on LDL-C. Consequently, we
aimed to perform a systematic review and meta-analysis of the clinical evidence available to
date to better define its efficacy and tolerability profile.
Methods
The study is reported in accordance with the 2009 guidelines of the Preferred Reporting Items
for Systematic Reviews and Meta-analyses (PRISMA) statement (S1 PRISMA Checklist) [10],
and was registered in the PROSPERO database (registration code: CRD42019129687). Due to
the study design (meta-analysis), neither institutional review board approval nor patient
informed consent was required.
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Search strategy
PubMed (Medline), Web of Science, Google Scholar, and Scopus databases were searched,
with no language restriction, using the following search terms: (“Bempedoic acid” OR “ETC-
1002”) AND (“Trial” OR “Study”) [Search terms: ((“Bempedoic acid”) AND Study) OR ((Bem-
pedoic acid) AND Trial) OR (ETC-1002 AND Study) OR (ETC-1002 AND Trial))]. The wild-
card term “�” was used to increase the sensitivity of the search strategy, which was limited to
studies in humans. The reference lists of identified papers were manually checked for addi-
tional relevant articles. Additional searches for potential trials included the references of
review articles on bempedoic acid, and the abstracts from selected scientific conferences on
the subject of the meta-analysis. Literature was searched from inception to 5 August 2019.
All abstracts were screened by 2 reviewers (FF and AFGC) in an initial process to remove
ineligible articles. The remaining articles were obtained in full-text and assessed again by the
same 2 researchers, who evaluated each article independently and carried out data extraction
and quality assessment. Disagreements were resolved by discussion with a third party (MB).
Study selection criteria
Original studies were included if they met the following criteria: (i) were a phase II or III RCT
with either multicenter or single-center design, (ii) investigated the effect of bempedoic acid
on plasma lipids or high-sensitivity C-reactive protein (hsCRP), (iii) tested the safety of bem-
pedoic acid in short- and middle-term administration, and (iv) reported all the adverse events
(AEs) that occurred during the treatment.
Studies that lacked a control-treated group for comparison with bempedoic acid were
excluded.
Data extraction
Data abstracted from the eligible studies were the following: (i) study registration code; (ii)
first author’s name; (iii) publication year; (iv) study phase; (v) main inclusion criteria and
underlying disease; (vi) treatment duration; (vii) study arms; (viii) number of participants in
the active and control group; (ix) age and sex of study participants, (x) baseline and outcome
data of total cholesterol (TC), LDL-C, high-density lipoprotein cholesterol (HDL-C), very-
low-density lipoprotein (VLDL), non-HDL-C, triglycerides (TGs), apolipoprotein (Apo) B,
Apo A-1, and hsCRP; and (xi) discontinuation of treatment and AEs that occurred during the
trials. Safety outcomes included: AEs, serious AEs, study-drug-related AEs, AEs leading to dis-
continuation of treatment, death, major adverse cardiac events, muscle-related AEs, arthralgia,
gout, back pain, pain in extremity, pruritus, rash, new onset hypertension, headache, fatigue,
dizziness, dyspepsia, abdominal pain, nausea, constipation, diarrhea, nasopharyngitis, sinusi-
tis, cough, dyspnea, upper respiratory tract infection, bronchitis, urinary tract infection, vulvo-
vaginal mycotic infection, new onset or worsening diabetes, neurocognitive disorders, vertigo,
increase in blood creatinine level, decrease in glomerular filtration rate, creatine kinase (CK)
elevation serum uric acid (SUA) elevation, and liver enzyme (transaminase and gamma-gluta-
myl transferase) elevation. All the verbatim terms for the AEs were coded to preferred term
and System Organ Class with the use of the Medical Dictionary for Regulatory Activities
(MedDRA).
Missing or unpublished data were sought by trying to contact authors or sponsors via e-
mail, and, in cases of no response, repeated messages were sent. Data extraction and database
typing were performed by 2 authors (AFGC and FF) and reviewed by a third author (MB)
before the final analysis. Doubts were resolved by mutual agreement among the authors.
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Risk of bias evaluation
A systematic evaluation of risk of bias in the included studies was performed using the Cochrane
tool [11]. The items used were the following: adequacy of sequence generation, blinding, address-
ing of dropouts (incomplete outcome data), allocation concealment, selective outcome reporting,
and other probable sources of bias [12]. Risk of bias assessment was performed by 2 reviewers (FF
and AFGC) independently; disagreements were resolved by a consensus-based discussion. Each
item was judged as high, low, or unclear risk of bias. A trial with high risk of bias in the randomi-
zation or blinding items was judged as having high risk of bias overall.
Data synthesis
All analyses were performed with Comprehensive Meta-Analysis (CMA) version 3 software
(Biostat, Englewood, NJ) [13]. Changes in continuous outcomes were calculated for each study
arm by subtracting the value at baseline from the one after intervention. All values were
expressed as percent change from baseline. Standard deviations (SDs) of the mean differences





(2R × SDpre × SDpost)], assuming a correlation coefficient (R) of 0.5. If the outcome measures
were reported in the original articles as median and interquartile range (or 95% confidence
interval [CI]), mean and SD values were obtained as described by Wan et al. [15]. In case stan-
dard error of the mean (SEM) was only reported as a dispersion measure, SD was estimated
using the following formula: SD = SEM ×
p
n, with n being the number of individuals. To han-
dle the double-counting problem in trials comparing different treatments against a single con-
trol group, individuals within the control group were divided by the required comparisons.
Meta-analyses were conducted using a fixed-effect model or a random-effect model (using the
DerSimonian–Laird method) and the generic inverse variance method based on the moderately
low (<50%) or high (�50%) inter-study heterogeneity, which was quantitatively assessed using
the Higgins index (I2) [16]. Effect sizes for lipid and hsCRP changes were expressed as MDs and
95% CIs. For safety analyses, odds ratios (ORs) and 95% CIs were calculated using the Mantel–
Haenszel method [17]. If 1 or more outcomes could not be extracted from a study, the study was
removed from the analysis involving those outcomes. AEs were included in the analysis only if
occurring in at least 2 of the selected clinical trials. The efficacy analysis was performed on the
safety population; the analysis of safety data was based on the intention-to-treat population.
For the purpose of evaluating the influence of each study on the overall effect size, sensitiv-
ity analysis was conducted using the leave-one-out method (i.e., repeating the analysis after
omitting 1 study at a time) [18]. Two-sided p-values� 0.05 were considered statistically signif-
icant for all tests.
If statistical heterogeneity was detected, attempts to identify the sources of heterogeneity and
potential publication biases were made through the visual inspection of Begg’s funnel plot asym-
metry, and carrying out the Begg’s rank correlation test and Egger’s linear regression test [19]. The
Duval and Tweedie “trim and fill” method was used to adjust the analysis for the effects of publica-
tion bias [20]. In case of a significant result, the number of potentially missing studies required to
make the p-value non-significant was estimated by using the classical fail-safe N method as another
marker of publication bias. Two-sided p-values� 0.05 were considered statistically significant.
Results
Flow and characteristics of the included studies
We identified 248 published abstracts. Of these, 238 were excluded because they were not orig-
inal articles. All the other 10 studies met the inclusion criteria and were carefully assessed and
PLOS MEDICINE Pooled analysis on efficacy and safety of bempedoic acid
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reviewed. On the basis of the established eligibility criteria, all 10 RCTs were included in the
meta-analysis [9,21–29]. The study selection process is shown in Fig 1.
Eligible studies were published between 2013 and 2019. Follow-up periods ranged between
4 and 52 weeks, and several treatment schedules were tested. All trials were parallel and multi-
center [9,21–26,28,29] or single-center [27]. Enrolled individuals were statin-intolerant indi-
viduals [9,21,24,28], patients with type 2 diabetes [21,27], or patients affected by
hypercholesterolemia despite statin treatment [21–23,25,26,29]. The main characteristics of
the selected studies are summarized in Table 1.
Risk of bias evaluation
The studies reported sufficient information regarding sequence generation, allocation conceal-
ment, blinding of participants, personnel, and outcome assessment. Details of the risk of bias
evaluation are reported in Table 2.
Effect of bempedoic acid on selected laboratory parameters
Meta-analysis of available data showed that bempedoic acid significantly reduced TC (n =
3,485; MD −14.94%; 95% CI −17.31%, −12.57%; p< 0.001; I2 = 76.1%) (Fig 2), non-HDL-C (n
= 3,485; MD −18.17%; 95% CI −21.14%, −15.19%; p< 0.001; I2 = 87.2%) (Fig 3), LDL-C (n =
3,483; MD −22.94%; 95% CI −26.63%, −19.25%; p< 0.001; I2 = 77.3%) (Fig 4), LDL particle
number (n = 441; MD −20.67%; 95% CI −23.84%, −17.48%; p< 0.001; I2 = 0%) (Fig 5), Apo B
(n = 3,402; MD −15.18%; 95% CI −17.41%, −12.95%; p< 0.001; I2 = 81.4%) (Fig 6), HDL-C (n
= 3,453; MD −5.83%; 95% CI −6.14%, −5.52%; p< 0.001; I2 = 33.4%) (Fig 7), and hsCRP (n =
3,179; MD −27.03%; 95% CI −31.42%, −22.64%; p< 0.001; I2 = 0%) (Fig 8). Furthermore,
Fig 1. Flow chart of the number of studies identified and included in the meta-analysis. Data were pooled from 10
trials comprising 26 treatment arms, which included overall 3,788 individuals, with 2,460 in the active arm and 1,328
in the control arm.
https://doi.org/10.1371/journal.pmed.1003121.g001
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bempedoic acid had a barely detectable significant effect on HDL-C particle number (n = 271;
MD −3.21%; 95% CI −6.40%, −0.02%; p = 0.049; I2 = 43.3%) (Fig 9).
There were no significant effects on TGs (n = 2,954; MD −1.51%; 95% CI −3.75%, 0.74%; p
= 0.189; I2 = 15.1%) (Fig 10), VLDL particle number (n = 271; MD 3.79%; 95% CI −9.81%,
17.39%; p = 0.585; I2 = 35.1%) (Fig 11), and Apo A-1 (n = 382; MD −1.83%; 95% CI −5.23%,
1.56%; p = 0.290; I2 = 50.1%) (Fig 12). When the largest study (the CLEAR Harmony trial) [23]
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the effect sizes were robust in the leave-one-out sensitivity analysis (S1–S4 Figs) and not
mainly driven by a single study.
Visual inspection of Begg’s funnel plots did not reveal any asymmetry, suggesting no publi-
cation bias for the effect of bempedoic acid on the investigated parameters (S6 Fig).
Duval and Tweedie’s “trim and fill” method yielded 1 potentially missing study on the left
side of the plot for TC, increasing the effect size to −15.27% (95% CI −17.61%, −12.92%); 4
potentially missing studies on the left side of the plot for HDL-C, lowering the effect size to
−5.88% (95% CI −6.18%, −5.57%); 1 potentially missing study on the right side of the plot for
HDL particle number, lowering the effect size to −1.86% (95% CI −4.86%, 1.13%); 4 potentially
missing studies on the left side of the plot for non-HDL-C, increasing the effect size to −-
20.15% (95% CI −23.73%, −16.57%); 3 potentially missing studies on the left side of the plot
for LDL-C, increasing the effect size to −25.17% (95% CI −29.55%, −20.79%); 2 potentially
missing studies on the left side of the plot for LDL particle number, lowering the effect size to
−21.85% (95% CI −24.74%, −18.96%); 1 potentially missing study on the right side of the fun-
nel for VLDL particle number, increasing the effect size to 8.55% (95% CI −4.01%, 21.11%); 2
potentially missing studies on the left side of the plot for Apo A-1, lowering the effect size to
−3.77% (95% CI −7.33%, −0.21%); and 3 potentially missing studies on the right side of the
Fig 2. Forest plot displaying mean difference and 95% confidence intervals for the effect of bempedoic acid on
plasma levels of total cholesterol.
https://doi.org/10.1371/journal.pmed.1003121.g002
Fig 3. Forest plot displaying mean difference and 95% confidence intervals for the effect of bempedoic acid on
plasma levels of non-high-density lipoprotein (HDL) cholesterol.
https://doi.org/10.1371/journal.pmed.1003121.g003
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plot for hsCRP, lowering the effect size to −25.69% (95% CI −29.89%, −21.48%). However, nei-
ther Begg’s rank correlation nor Egger’s linear regression confirmed the presence of publica-
tion bias for the analyses (p> 0.05 for all) (S2 Table).
The classic fail-safe N test suggested that the following number of studies with negative
results would be needed to bring the estimated effect size for each outcome to a non-significant
level: 2,280 studies for TC (p< 0.001 for the test), 838 studies for HDL-C (p< 0.001 for the
test), 2 studies for HDL particle number (p = 0.017 for the test), 2,004 studies for non-HDL-C
(p< 0.001 for the test), 2,053 studies for LDL-C (p< 0.001 for the test), 263 studies for LDL
particle number (p< 0.001 for the test), 1,308 studies for Apo B (p< 0.001 for the test), and
188 studies for hsCRP (p< 0.001 for the test). The individual analyses are included in S3
Table.
Safety analysis
Bempedoic acid was positively associated with an increased risk of discontinuation of treat-
ment (n = 3,731; OR 1.37; 95% CI 1.06, 1.76; p = 0.015; I2 = 0%), elevated SUA (n = 569; OR
3.55; 95% CI 1.03, 12.27; p = 0.045; I2 = 0%), elevated liver enzymes (n = 2,363; OR 4.28; 95%
CI 1.34, 13.71; p = 0.014; I2 = 0%), and elevated CK (n = 2,718; OR 3.79; 95% CI 1.06, 13.51;
p = 0.04; I2 = 0%), but it was strongly associated with a decreased risk of new onset or worsen-
ing diabetes (n = 2,498; OR 0.59; 95% CI 0.39, 0.90; p = 0.01; I2 = 0%) (Fig 13).
These findings were robust in the leave-one-out sensitivity analyses (S6 Fig). However,
when the data from the largest study (the CLEAR Harmony trial) [23] were excluded from the
Fig 4. Forest plot displaying mean difference and 95% confidence intervals for the effect of bempedoic acid on
plasma levels of low-density lipoprotein (LDL) cholesterol.
https://doi.org/10.1371/journal.pmed.1003121.g004
Fig 5. Forest plot displaying mean difference and 95% confidence intervals for the effect of bempedoic acid on
plasma levels of low-density lipoprotein (LDL) particle number.
https://doi.org/10.1371/journal.pmed.1003121.g005
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meta-analysis, the effect sizes for the safety outcomes lost their statistical significance (S1
Table).
The incidence of the other AEs did not differ between groups (S4 Table). Considering the
reasons for treatment discontinuation in included trials that reported all or part of them (S5
Table), it was not possible to identify the responsible reasons of the effect size of Fig 6 (S7 Fig).
Visually, the funnel plot of standard error by log OR was slightly asymmetric only for risk
of discontinuation of treatment. This asymmetry was imputed to 6 potentially missing studies
on the right side of the funnel plot, increasing the estimated risk to 1.55 (95% CI 1.22, 1.97) (S8
Fig). The presence of publication bias for the analysis was confirmed by Egger’s linear regres-
sion (p = 0.005), but not by Begg’s rank correlation (p = 0.298). The classic fail-safe N test sug-
gested that 1 study with a negative result would be needed to bring the estimated risk of CK
elevation to a non-significant level (p = 0.042 for the test), and 2 studies with negative results
would be needed to bring the estimated risk of transaminase elevation to a non-significant
level (p = 0.021 for the test). The individual analyses are included in S6 Table.
Discussion
Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (statins) represent the first-
line treatment for dyslipidemia, being able to reduce LDL-C by 30%–50% and subsequently
Fig 6. Forest plot displaying mean difference and 95% confidence intervals for the effect of bempedoic acid on
plasma levels of apolipoprotein B.
https://doi.org/10.1371/journal.pmed.1003121.g006
Fig 7. Forest plot displaying mean difference and 95% confidence intervals for the effect of bempedoic acid on
plasma levels of high-density lipoprotein (HDL) cholesterol.
https://doi.org/10.1371/journal.pmed.1003121.g007
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decrease the incidence of CV events [30]. Despite the highly favorable benefit/risk profile of
statins, a large number of patients are statin intolerant or need additional lipid-lowering drugs
to reach optimal LDL-C levels [3]. The current meta-analysis shows that bempedoic acid safely
reduces LDL-C levels by about 23%, suggesting that it might be considered as an effective alter-
native or add-on therapy to statins or ezetimibe.
About 31%–49% or more of patients with hyperlipidemia do not achieve LDL-C goals with
current lipid-lowering therapies [31,32], and more than half of patients stop statin treatment
within 1 year of initiation [33]. Sixty percent of patients who discontinue statins report differ-
ent symptoms of drug intolerance as the main reason for discontinuation [34]. Statin intoler-
ance, usually characterized by myalgia, myositis, and/or myopathy, occurs in 2%–15% of
users, the estimate being strongly variable in epidemiological and rechallenging studies
[35,36]. Furthermore, large meta-analyses showed that statin treatment is associated with a
9%–13% increase in risk of developing diabetes [37]. However, scientifically unsupported con-
cerns about statin safety spread by mass media lead to the formation of a negative image of
these drugs and increase of their cessation rate [38].
Additional treatments of dyslipidemia include ezetimibe (second-line) and fenofibrate
(third-line). Ezetimibe, in combination with statin therapy, lowers LDL-C by an additional
20% or so [39] and significantly reduces the risk of major adverse CV events, non-fatal myo-
cardial infarction, and non-fatal stroke compared with statins alone, with less or no effect on
fatal endpoints [40]. A simulation based on adding ezetimibe in a huge statin-treated cohort
suggests that the percentage of patients with LDL-C > 1.8 mmol/l and>2.4 mmol/l would fall
from 65% to 38% and from 25% to 12%, respectively [41].
Fig 8. Forest plot displaying mean difference and 95% confidence intervals for the effect of bempedoic acid on
plasma levels of high-sensitivity C-reactive protein.
https://doi.org/10.1371/journal.pmed.1003121.g008
Fig 9. Forest plot displaying mean difference and 95% confidence intervals for the effect of bempedoic acid on
plasma levels of high-density lipoprotein (HDL) particle number.
https://doi.org/10.1371/journal.pmed.1003121.g009
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Fibrates are less effective on LDL-C levels, with their main indication being moderate-to-
severe hypertriglyceridemia, such that they are rarely used in cardiology settings. However, a
large meta-analysis of 16,112 patients showed evidence for a protective effect compared to pla-
cebo for the primary composite outcome of non-fatal myocardial infarction, non-fatal stroke,
and vascular death [42]. Besides, patients with very high baseline LDL-C level or very high or
extreme global CV risk need additional lipid-lowering drugs to optimize the lipid profile [43],
especially in light of the most recent international recommendations [44,45]. Monoclonal anti-
bodies that target proprotein convertase subtilisin/kexin type 9 (PCSK9) have recently been
demonstrated to dramatically reduce LDL-C level (even over 60%) in the majority of cases,
while significantly reducing CV risk; however, their cost–benefit ratio is yet under discussion,
and in many countries their use is limited due to strict reimbursement rules [46]. In this con-
text, there is yet place for the development of new less-expensive, effective/safe lipid-lowering
drugs.
By analyzing data from 10 phase II and phase III RCTs including a total of 3,788 patients,
we confirmed that bempedoic acid significantly reduced TC (by 15%), non-HDL-C (by
18.2%), LDL-C (by 22.9%), LDL particle number (by 20.7%), Apo B (by 15.2%), and hsCRP
(by 27%), while negatively affecting serum levels of HDL-C (−5.8%) and HDL particle number
(−3.2%). These findings strengthen the unpowered data previously reported by Wang et al.,
based on only 625 patients [47]. These findings could also be quantitatively relevant, since they
have usually been obtained when bempedoic acid is administered on top of an effective lipid-
lowering treatment, with a quite good safety and tolerability profile.
Our results also confirmed that bempedoic acid therapy is overall safe and well tolerated,
with no significant increase of serious AEs. However, an increase of drug discontinuation and
Fig 10. Forest plot displaying mean difference and 95% confidence intervals for the effect of bempedoic acid on
plasma levels of triglycerides.
https://doi.org/10.1371/journal.pmed.1003121.g010
Fig 11. Forest plot displaying mean difference and 95% confidence intervals for the effect of bempedoic acid on
plasma levels of very-low-density lipoprotein (VLDL) particle number.
https://doi.org/10.1371/journal.pmed.1003121.g011
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elevations of SUA, transaminase, and CK were observed. The detailed analysis of the reasons
for discontinuation (see S5 Table) reported in the available trials does not give any clear pat-
tern that could explain the 37% increased risk of discontinuation of bempedoic acid in com-
parison to placebo; this issue, however, needs to be further investigated. As for the other
adverse effects possibly related to bempedoic acid, it is important to emphasize that in the 4 tri-
als where CK increase was reported, it was observed in only 16 patients (of 1,792 investigated;
0.9%), and only single patients had a repeated and confirmed CK elevation greater than 5
times the upper limit of normal. More data with longer follow-up are also necessary to confirm
the risk of SUA increase with bempedoic acid (observed in only 3 trials, where SUA increase
was observed in 18/354 [5%]), as well as the risk of transaminase increase (observed in 5 trials,
where transaminase increase was observed in only 1.1% of patients [20/1,823] in active-treated
group). It is also worth emphasizing that bempedoic acid, due to its mechanism of action, does
not increase the risk muscle-related side-effects and significantly reduces the risk of worsening
or new onset diabetes by about 40% (however, based only on 2 available studies)—AEs that
might be relatively often observed in statin trials, especially for high- and very-high-risk
patients requiring intense therapy.
In this context, bempedoic acid seems to be an interesting option as an overall safe drug to
be easily associated to statins and ezetimibe. In particular, the drug will be marketed as mono-
therapy or in a single pill with ezetimibe for the management of statin-intolerant patients.
Considering the different mechanism of action of bempedoic acid and ezetimibe, the high
safety profile of both drugs, and the lack of interaction risk between them, it is expected that
this association will be a relatively effective and safe lipid-lowering treatment.
The main limitation of this meta-analysis is related to the relatively small number of
patients involved in the studies, which were often short or middle term, as well as their hetero-
geneity (including different populations that were investigated, i.e., patients with type 2 diabe-
tes, hypercholesterolemia, or statin intolerance). Moreover, heterogeneity of effects is
moderate to large across most of the biochemical outcomes. Data on decreased CV events and
mortality are lacking for bempedoic acid as well [48].
In conclusion, the current meta-analysis demonstrates an acceptable safety profile and mul-
tiple positive effects of bempedoic acid on lipid profile and hsCRP serum levels.
Further data on the cost–benefit efficacy of bempedoic acid treatment will come from the
CLEAR Outcomes study, a phase III, event-driven, randomised, multicenter, double-blind,
placebo-controlled trial designed to evaluate whether treatment with bempedoic acid reduces
the risk of CV events. The primary endpoint of the study is the effect of bempedoic acid on
major adverse CV events (CV death, non-fatal myocardial infarction, non-fatal stroke, and
coronary revascularization). The enrollment ended in November 2019 [49].
Fig 12. Forest plot displaying mean difference and 95% confidence intervals for the effect of bempedoic acid on
plasma levels of apolipoprotein A-1.
https://doi.org/10.1371/journal.pmed.1003121.g012
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Fig 13. Forest plot comparing the risk of adverse events statistically associated with bempedoic acid treatment.
https://doi.org/10.1371/journal.pmed.1003121.g013
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